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Abstract
Introduction: The feasibility and accuracy of text messaging to monitor events after influenza 
vaccination throughout pregnancy and the neonatal period has not been studied, but may be 
important for seasonal and pandemic influenza vaccines and future maternal vaccines.
Methods: This prospective observational study was conducted during 2013–2014 and analyzed 
in 2015–2016. Enrolled pregnant women receiving inactivated influenza vaccination at a 
gestational age <20 weeks were sent text messages intermittently through participant-reported 
pregnancy end to request fever, health events, and neonatal outcomes. Text message response 
rates, Day 0–2 fever (≥ 100.4°F), health events, and birth/neonatal outcomes were assessed.
Results: Most (80.2%, n=166) eligible women enrolled. Median gestational age was 8.9 
(SD=3.9) weeks at vaccination. Response rates remained high (80.0%–95.2%). Only one Day 0–2 
fever was reported. Women reported via text both pregnancy-and non-pregnancy–specific health 
events, not all associated with medical visits. Most pregnancy-specific events in the electronic 
medical record (EMR) were reported via text message. Of all enrollees, 84.9% completed the 
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study (131 reported live birth, ten reported pregnancy loss). Two losses reported via text were not 
medically attended; there was one additional EMR-identified loss. Gestational age and weight at 
birth were similar between text message–reported and EMR-abstracted data and 95% CIs were 
overlapping for proportions of prematurity, low birth weight, small for gestational age, and major 
birth defects, as identified by text message–reported versus EMR-abstracted plus text message–
reported versus EMR-abstracted data only.
Conclusions: This study demonstrated the feasibility of text messaging for influenza vaccine 
safety surveillance sustained throughout pregnancy. In these women receiving inactivated 
influenza vaccination during pregnancy, post-vaccination fever was infrequent and a typical 
pattern of maternal and neonatal health outcomes was observed.
INTRODUCTION
Rapid monitoring of vaccine safety is an important component of national and international 
pandemic influenza plans, and pregnant women are a target population for vaccination, 
owing to increased risk of influenza morbidity and mortality.1–8 Such monitoring may also 
be important for other vaccines for pregnant women, particularly when medical records are 
not readily available.9,10
Text messaging can be used to rapidly collect individualized data on both medically attended 
and non-attended events in large populations over a long period of time.11 Although the use 
of text messaging for vaccine adverse event reporting in children has been successful,12,13 
and limited studies have assessed its use in pregnant women,14–16 the feasibility of its use to 
monitor vaccine safety in women enrolled early in pregnancy and monitored throughout 
pregnancy and the neonatal period has yet to be reported. Such a system would ideally 
capture immediate post-vaccination events, such as fever, short-term adverse events in the 
first 42 days post-vaccination, longer-term pregnancy-related conditions, and pregnancy and 
neonatal outcomes.
The goal of this prospective study was to assess the:
1. feasibility of recruiting pregnant women <20 weeks gestational age (GA) to 
participate in a text messaging—based vaccine adverse event monitoring 
program after receipt of inactivated influenza vaccine (IIV); and
2. utility of text messaging to monitor health events, including fever frequency on 
vaccination and next 2 days (Days 0–2), health events during pregnancy, 
pregnancy outcomes, and neonatal outcomes.
METHODS
This prospective observational study was conducted during the 2013–2014 influenza season 
at a family planning clinic and three obstetrics and gynecology practices. All four sites are 
affiliated with New York-Presbyterian Hospital/Columbia University Medical Center (NYP/
CUMC) in New York City. One practice serves a primarily publicly insured and Latino 
population, and three a commercially insured, primarily non-minority, English-speaking one. 
Patients from both sites deliver at one of two NYP sites. All vaccination decisions were 
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made by patients and healthcare providers as part of usual practice; it was not routine 
practice to provide antipyretics at vaccination. CUMC’s IRB approved the study and the 
Centers for Disease Control and Prevention relied on the CUMC IRB. Analyses were 
conducted in 2015–2016.
Study Population
Women were eligible to enroll if they (1) were pregnant with a GA <20 weeks by last 
menstrual period and/or ultrasound; (2) were aged ≥18 years; (3) elected to receive IIV 
(trivalent) at time of enrollment; (4) had a cell phone with text messaging capabilities; (5) 
were English or Spanish speaking; and (6) were willing to report via text message through 
pregnancy end. Exclusion criteria included (1) decision to not continue pregnancy at time of 
enrollment; (2) temperature ≥ 100.4°F at vaccination; (3) anti-pyretic administration within 
6 hours pre-vaccination or stated intent to use prophylactically; and (4) inability to read text 
messages. Receipt of additional vaccines at enrollment or any time during pregnancy was 
not an exclusion criterion.
At the time of vaccination, eligible women were approached. After consent, they completed 
an intake form, reviewed text message procedures, and enrolled by sending a text message to 
the text messaging platform. They also received a digital thermometer and a paper diary in a 
pre-addressed, pre-stamped envelope to return after the 2-day fever observation period; these 
procedures were not part of usual practice.
Participants were instructed to take their oral temperature at least once daily, or more often if 
they felt febrile, from Day 0 (day of vaccination) and continuing over the next 2 days (Days 
1–2), and were sent messages nightly to report their highest temperature, antipyretic use, and 
care sought. Text messages were next sent on Days 7, 14, 28, and 42 to capture short-term 
adverse events temporally associated with vaccination. From Day 70 onward, text messages 
were sent once a month for 4 months, then biweekly for 4 weeks, and then weekly. All text 
messages first assessed whether the participant was still pregnant and, if affirmative, 
continued into an interactive message cascade assessing any health problems. This included 
both close-ended queries assessing specifically for vaginal bleeding, contractions/cramping, 
and fever, and open-ended questions for other health events. If a participant reported she was 
no longer pregnant, a cascade assessed the pregnancy outcome (i.e., delivery, pregnancy loss, 
or termination). After reporting a delivery, GA, birth weight, and any neonatal health 
problems were assessed via open-ended questions. After reporting a pregnancy loss or 
termination, GA at time of the event was elicited. All cascades ended with a note informing 
women to contact their healthcare provider if they needed medical care. Messages were 
stopped when a pregnancy outcome was reported or 4 weeks after due date. Ten pregnancy-
related health tips were sent between assessments through Day 175 to aid in study 
engagement. All messages were sent in English or Spanish based on patient preference.
Research staff reviewed incoming responses daily and initiated contact via phone with non-
responders to collect missing data and answer technical questions. Using an electronic 
medical record (EMR) abstraction tool, vaccinations and all healthcare visits (prenatal, 
ambulatory, emergency department, and hospital) to NYP/CUMC throughout pregnancy 
were recorded. An exit survey was conducted.
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Measures
Primary outcomes included the proportion of (1) eligible patients enrolled; (2) data reported 
on Days 0–2; and (3) data reported through the end of pregnancy. Secondary outcomes 
included (1) fever (temperature ≥ 100.4°F/38°C) on Days 0–2 post-vaccination; (2) 
pregnancy-specific events (e.g., gestational diabetes) reported; (3) pregnancy outcomes 
(delivery, pregnancy loss [spontaneous abortion {SAB} defined as loss at <20 weeks or 
stillbirth ≥ 20 weeks] or termination); and (4) proportion of preterm (< 37 weeks gestation), 
low birth weight (< 2,500 grams), and small for gestational age births and major birth 
defects.17–20
Statistical Analysis
The associations between baseline text message plan and frequency and response rates and 
study completion were assessed using chisquare tests. Reported health events were 
described. Pregnancy and neonatal outcomes using text message—reported only versus both 
sources (text plus EMR-abstracted) versus EMR-abstracted data only, including 95% CIs as 
applicable, were assessed. Pregnancy outcomes used the number of pregnant women as the 
denominator; neonatal outcomes used the number of live new-borns. All analyses were 
conducted in SPSS, version 23.
RESULTS
Nearly all approached women (97.1%) had a cell phone with text messaging. One hundred 
sixty-six women enrolled, 80.2% of those eligible (Appendix Figure 1, available online). 
Median GA at vaccination was 8.9 weeks (Table 1). Nearly all (90.4%) had unlimited text 
messaging plans and sent text messages daily (94.0%), but few (9.0%) had received text 
messages from their doctor or their doctor’s office. All received only IIV on enrollment, and 
70.5% had documented receipt of tetanus—diphtheria—pertussis vaccine during the same 
pregnancy.
Daily text message response rates were high on Days 0–2 (Figure 1A) with 84.9% providing 
data on all 3 days. There was no statistically significant difference in responding for all 3 
days by text message plan (88.9% limited vs 84.7% unlimited plan, p=0.73) or frequency of 
baseline text message use (84.0% text daily vs 100.0% text less than daily, p=0.17). Only 
one participant reported a Day 0–2 fever (100.4°F on Day 1 via diary, 100.3°F via text 
message). Three quarters (77.7%) of participants returned the paper temperature diary. Most 
(n=141, 84.9%) continued to report through pregnancy end. Seventeen women stopped 
reporting (median stopped reporting 42 days; interquartile range, 21–161 days). Eight 
women never responded via text or phone. There was no difference in the 25 women who 
stopped or were non-responders versus those completing the study based on kind of text 
message plan (11.1% limited vs 16.0% unlimited plan, p=0.70) or baseline frequency of text 
message use (15.4% text daily vs 10.0% text less than daily, p=0.64). Two thirds of women 
received a phone call owing to not responding or questionable response. Of those, 84.8% 
remained active after the phone contact. Of the 95 remaining active, 51.6% only required 
one call.
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Response rates remained high throughout pregnancy (Figures 1B and 1C). In both the Day 
7–42 and Day ≥ 70 periods, women reported via text both pregnancy-specific and non-
pregnancy—specific health events. These included pre-specified responses for vaginal 
bleeding, contractions/cramping and fever, as well as in-depth free-text responses, not all of 
which resulted in medical visits (Table 2, Appendix Table 1, available online). On EMR 
review, there were pregnancy-related events that were not reported via text message. These 
included emergency department visits for vaginal bleeding (n=3), contractions (n=3), 
anemia/syncope (n=1), and oligohydramnios (n=1).
Of the 141 participants completing the study, 131 reported a live birth and ten a pregnancy 
loss. Most (n=9) reporting a loss also reported the GA (8–23 weeks). Pregnancy loss was 
documented in the EMR for eight of the ten participants. One additional loss was noted in 
the EMR in a woman who last reported via text message on Day 14 post-vaccination and 
had a loss at Day 28 (15 5/7 weeks GA). The proportion of women with an SAB was similar 
when using text message reports alone versus text message plus EMR-abstracted data versus 
EMR-abstracted data alone (Table 3). There were three losses not classified as SABs: one 
stillbirth at 20 weeks, one elective termination at 22 weeks due to premature rupture of 
membranes and inevitable neonatal demise, and one pregnancy where it was unclear whether 
it was an SAB or elective termination prior to 18 weeks gestation. The first two were noted 
by text message and EMR abstraction; the third was noted by text message only.
There were 151 live-birth deliveries (131 reported via text message and an additional 20 
from the EMR for women who stopped reporting or never reported). There were 145 
singleton births, five sets of twins, and one set of triplets, for a total of 158 infants. Of the 
131 deliveries reported via text message, EMR records were available for 115. Of those who 
reported birth via text, most (96.9%) reported a usable GA with a range of 30–42 weeks. 
When comparing GA reported via text message versus EMR-abstracted data, the text 
message–reported GA was within 7 days for 97.3% of records. Eight mothers reported a 
preterm birth via text message; all were confirmed by EMR review. Two additional preterm 
births were found in the EMR in women who stopped reporting via text message, for a total 
of ten. The proportion with preterm births was similar using the three data source categories 
(Table 3).
Birth weight reported via text message was within 8% of that recorded in the EMR for all 
infants and 5% for all but two infants. There were 11 low birth weight infants reported via 
text message, all of which were confirmed on EMR review. Three additional low birth 
weight infants were found in the EMR, two in a woman who stopped reporting and one in a 
woman with multiple births who reported for one infant only, for a total of 14 overall, with 
similar proportions from the three data source categories (Table 3). Although infant sex was 
not captured via text message, but would be needed to accurately assess small for gestational 
age using the Fenton growth chart,21 sex was abstracted for those with an EMR record and 
defaulted to male for the remaining for the most conservative estimate. There were six small 
for gestational age infants identified by text message alone, 11 infants each using text 
message plus EMR-abstracted data and EMR-abstracted data alone (Table 3).
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Two major birth defects in two infants (hip dysplasia, situs in versus/hypospadias) were 
reported via text message, both EMR confirmed.18 Two other major birth defects were 
identified on EMR abstraction: penile webbing in two infants whose mothers had stopped 
reporting (one stopped 168 days before delivery and the other 36 days), resulting in similar 
proportions by data source (Table 3). Four minor defects were not reported by text message 
(three isolated penile torsions, one partial syndactyly of second and third toes). There were 
15 other pregnancies with neonatal problems not considered to be birth defects. Thirteen of 
these women sent free text messages regarding neonatal health problems, eight of which 
were also identified in the EMR, including acid reflux, hypoglycemia (n=2), tachypnea, 
infection, jaundice (n=2), and prematurity (sent as free text in addition to providing GA). 
One woman identified jaundice by text message post-hospital discharge not documented in 
the birth hospital EMR. One woman indicated via text message that there was a problem but 
did not specify. Three women texted there was not a problem but one was identified in the 
EMR (blood ABO incompatibility in one infant, two infants with multiple issues in the 
neonatal intensive care unit). Two women did not send final pregnancy outcomes via text but 
a neonatal problem (hyperbilirubinemia, hypoglycemia) was identified in the EMR. When 
assessing EMR-confirmed outcomes for the 25 women who stopped reporting/never 
reported to the 141 who completed the study, pregnancy and neonatal outcomes were similar 
(Appendix Table 2, available online).
An exit survey was completed in 129 of 131 women reporting delivery. Nearly all (96.9%) 
were satisfied with the study and 94.6% would take part in a future text message study. Most 
(76.6%) preferred text message, whereas 4.7% preferred the paper diary. Most women 
(>95%) were satisfied with each of the different text message frequencies. Nine women 
reported not liking the ongoing questions that started with asking if “they were still 
pregnant.” Nearly all women (97.6%) believed that influenza vaccine is safe. Few (5.5%) 
had perceived side effects from influenza vaccine, including being tired (n=1), cold or “flu-
like” symptoms (n=5), and fever (n=1). Finally, 14.2% reported that taking part in the study 
positively affected how they felt about vaccine safety, with the remaining reporting no or an 
unknown effect; there were no reports of a negative impact on attitudes.
DISCUSSION
This study demonstrates the feasibility of text messaging surveillance throughout pregnancy 
after influenza vaccination, including pregnancy and neonatal outcomes, across a bilingual 
population of different socioeconomic levels. Both medically attended and non-attended 
health events were identified, and both pregnancy losses and deliveries occurring outside the 
medical center were captured as well. Neonatal outcomes were identified with good 
correlation between text message—reported and EMR-recorded gestational age and weight. 
All major EMR-documented birth defects were identified by text message except penile 
webbing; however, minor birth defects, primarily penile torsion, were not identified. Similar 
to previous literature, post-vaccination fever was infrequent,22,23 and pregnancy-specific 
health events were few.22,24–26 Proportions of preterm births, low birth weight, and SGA 
births were consistent with those reported in national surveillance literature.27 Text message 
surveillance, with its ability to rapidly send thousands of messages from a centralized 
location, could enhance vaccine safety monitoring for pregnant women for clinical and 
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public health use, including during an influenza pandemic or other outbreak, when such 
large-scale surveillance may be needed to detect potentially less common adverse events. 
The study also supports the potential of text messaging to collect product safety information 
in clinical research studies involving pregnant women.
The ability to capture non-medically attended events may be important because pregnant 
women and their providers may have concerns about vaccine safety and efficacy and the 
risks of influenza, and non-medically attended events can affect vaccination views.28 It may 
be helpful for reassurance from a vaccine safety surveillance perspective that all kinds of 
potential events are being captured. Interestingly, although there may have been a concern 
that involving women directly in reporting may make them more concerned about vaccine 
safety, the opposite was true. There was also an a priori concern of the study team about 
women being comfortable texting about sensitive topics. However, ten of 11 women with a 
pregnancy loss reported it via text message, as did all women with a child with a major birth 
defect, who were still reporting via text message at the time of the birth.
There were a number of lessons learned. Though it might be best to create a list of specific 
outcomes of importance with related text queries, it is valuable to maintain an open-ended 
question querying other events that pregnant women deem significant. Similarly, phone call 
follow-up may be needed for more precise information in those with a vaccine safety 
response of potential concern or for missing information; this could be more challenging in 
large-scale monitoring. For neonatal out-comes, the system needs to be able to capture 
multiple births. Additionally, depending on public health or research interest, more 
information may need to be captured including sex, GA in weeks and days, and neonatal 
intensive care unit versus well-baby/transitional nursery admission. A different message 
cascade might need to be developed for those infants admitted to the neonatal intensive care 
unit, for whom there may be multiple problems that may not be known right after birth or 
may be resolved by the time the mother replies to the text message in case of delay. In 
addition, although asking women if “they were still pregnant” was an important trigger 
question, it was not well received by a few women and likely should not be the opening 
message in a cascade. Also, as the messages were spaced so that women were not 
overwhelmed, the 1-month interval in the middle of the study may have been too long, 
leading to decreased event reporting. Finally, although the women were not asked to text 
about any urgent medical needs and all message cascades ended with a note to contact their 
healthcare provider if any medical care was needed, it is important that those instructions 
also be given upfront to women so that they do not mistakenly think they are texting their 
doctor’s office.
Limitations
The greatest strength of this study is that it is the first use of text message vaccine adverse 
event surveillance for pregnant women throughout pregnancy, not only in the immediate 
post-vaccination period as has been demonstrated.14–16,29 There are also a number of 
limitations. There could be under-reporting of pregnancy-specific outcomes, and there were 
15% of women for whom information was inadequate. In addition, this study took place in 
one academic medical center system during one influenza season; however, the study 
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population was relatively sociodemographically diverse. Finally, women had to be willing to 
enroll in a lengthy text message reporting study, but enrollment rates were high.
CONCLUSIONS
This study demonstrated the feasibility of text messaging for influenza vaccine safety 
surveillance throughout pregnancy. In addition, in these women receiving IIV during 
pregnancy, post-vaccination fever was infrequent and a typical pattern of maternal and 
neonatal health outcomes for pregnancies was observed.
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Figure 1. 
Text message response rates by day post-vaccination and response types. (A) Day 0–2 
responses to text messages assessing fever; (B) Day 7–42 responses to text messages 
assessing short-term adverse events temporally associated with vaccination; (C) Day 70–245 
responses to text messages assessing health events through the end of pregnancy, and 
pregnancy and neonatal outcomes.
Note: Response rates end on Day 245 due to having fewer than five participants from Day 
252–259. Denominator includes all women who had not yet reported a pregnancy outcome 
who were still within 2 weeks of their estimated due date.
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Table 1.
Characteristics of Study Population (N=166)
Characteristics Data
Age
 Median, years 32
  19–25 years 38 (22.9)
  26–34 years 75 (45.2)
  35–46 years 53 (31.9)
GA (by last menstrual period at vaccination)
 Median, weeks 8.9
 Range, weeks 3.9–19.5
 1–13 weeks (first trimester) 141 (84.9)
 14– <20 weeks (second trimester) 25 (15.1)
Primigravida 69 (41.6)
Ethnicity, Latina 96 (57.8)
Race (self-reported)
 White 73 (44.0)
 Black 15 (9.0)
 Asian 8 (4.8)
 Indigenous Latin American 7 (4.2)
 Multiracial 21 (12.7)
 Other 42 (25.3)
Primary language
 Spanish 55 (33.1)
 English 111 (66.9)
Insurance (at enrollment)
 Commerical 85 (51.2)
 Public 36 (21.7)
 Uninsured 45 (27.1)
Education
 Less than HS 11 (6.6)
 HS/trade/vocational school 38 (22.9)
 Some college 35 (21.1)
 College graduate 82 (49.4)
Type of text message plan
 Unlimited number of text messages per month 150 (90.4)
 Limited number of text messages per month/pay per text 9 (5.4)
 Don’t know 7 (4.2)
How often send text messages
 Never 1 (0.6)
 Daily 156 (94.0)
 Weekly 7 (4.2)
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Characteristics Data
 Monthly 1 (0.6)
 Less than once a month 1 (0.6)
Ever received text messages from their doctor or doctor’s office 15 (9.0)
Note: Data are n (%) unless otherwise noted.
GA, gestational age; HS, high school.
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